Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis

Journal of Infectious Diseases

Volumn 186, Issue 12, 2002, Pages 1808-1814

  Awomoyi, Agnes A ^a,d   Marchant, Arnaud ^a,b   Howson, Joanna M M ^c   McAdam, Keith P W J ^a   Blackwell, Jenefer M ^c   Newport, Melanie J ^a,c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d University of Maryland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; INTERLEUKIN 10; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN; PROTEIN SLC11A1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION REGULATION; GENE ISOLATION; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEREDITY; HUMAN; INFECTION SENSITIVITY; INTRACELLULAR TRANSPORT; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REPRODUCIBILITY; SLC11A1 GENE; TUBERCULOSIS; VACCINATION;

ADULT; ALLELES; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; GAMBIA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-10; MALE; MIDDLE AGED; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, GENETIC; TUBERCULOSIS, PULMONARY;

EID: 0037114921     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345920     Document Type: Article

References (46)

1. Nunn P. The global control of tuberculosis: What are the prospects? Scand J Infect Dis 2001; 33:329-32.
2. Fine PE. BCG: The challenge continues. Scand J Infect Dis 2001; 33:243-5.
3. World Health Organization/International Union against Lung and Tuberculous Disease. Anti-tuberculosis Drug Resistance in the World, 2000. Report no. 2, WHO/CDS/TB/2000.278. Geneva: World Health Organization, 2000.
4. Casanova JL. Abel L. Genetic dissection of immunity to mycobacteria: The human model. Anna Rev Immunol 2002; 20:581-620.
5. Gros P, Skamene E, Forget A. Genetic regulation of natural resistance to Mycobacterium boris BCG. J Immunol 1981; 127:2417-21.
6. Vidal SM, Malo D. Vogan K, Skamene E, Gros P. Natural resistance to infection with intracellular parasites: Isolation of a candidate for Bcg. Cell 1993; 73:469-85.
7. Liu J, Fujiwara TM, Buu NT, et al. Identification of polymorphisms and sequence variants in the human homologue of the mouse natural resistance-associated macrophage protein gene. Am J Hum Genet 1995; 56:845-53.
8. Bellamy R, Ruwende C, Corrah T, McAdam KPW, Whittle HC, Hill AVS. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338:640-4.
9. Cervino AC, Lakiss S, Sow O, Hill AV. Allelic association between the NRAMP1 gene and susceptibility to tuberculosis in Guinea-Conakry. Ann Hum Genet 2000;64:507-12.
10. Ryu S, Park YK, Bai GH, Kim SJ, Park SN, Kang S. 3′ UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans. Int J Tuberc Lung Dis 2000;4:577-80.
11. Gao PS, Fujishima S, Mao XQ, et al. Genetic variants of NRAMP1 and active tuberculosis in Japanese populations. International Tuberculosis Genetics Team. Clin Genet 2000;58:74-6.
12. Greenwood CMT, Fujiwara TM, Boothroyd LJ, et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large Aboriginal Canadian family. Am J Hum Genet 2000;67:405-16.
13. Blackwell JM, Barton CH, White JK, et al. Genomic organization and sequence of the human NRAMP gene: Identification and mapping of a promoter region polymorphism. Mol Med 1995;1:194-205.
14. Searle S, Blackwell JM, Evidence for a functional repeat polymorphism in the promoter region of human NRAMP1 that correlates with infectious versus autoimmune disease susceptibility. J Med Genet 1999;36:295-9.
15. Blackwell JM, Searle S, Goswani T, Miller EN. Understanding the multiple functions of Nramp1. Microbes Infect 2000;2:317-21.
16. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma receptor gene and susceptibility to mycobacterial infections in man. N Engl J Med 1996;335:1941-9.
17. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med 1996;335:1956-9.
18. Dorman SE, Holland SM. Mutation in the signal transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998;101:2364-9.
19. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
20. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991;174:1549-55.
21. Sterling TR, Dorman SE, Chaisson RE, et al. Human immunodeficiency virus-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001;33:976-82.
22. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Vol 2. Cold Spring Harbor. New York: Cold Spring Harbor Laboratory Press, 1989.
23. Sanjeevi CB, Miller EN, Dabadghao P, et al. Polymorphism at NRAMP1 and D2S1471 loci associated with juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:1397-404.
24. Blackwell JM, Goswami T, Evans CAW, et al. SLC11A1 (formerly NRAMP1) and disease resistance. Cell Microbiol 2001;3:773-84.
25. Abel L, Sanchez FO, Oberti J, et al. Susceptibility to leprosy is linked to the human NRAMP1 gene. J Infect Dis 1998;177:133-45.
26. Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in West Africans. Am J Trop Med Hyg 2001;65:733-5.
27. Pie S, Matsiota-Bernard P, Truffa-Bachi P, Nauciel N. Gamma interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of Salmonella typhimurium infection. Infect Immun 1996;64:849-54.
28. Rojas M, Olivier M, Gros P, Barrera LF, Garcia LF. TNF-α and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. J Immunol 1999;162:6122-31.
29. Vidal S, Tremblay ML, Govoni G, et al. The Ity/Lsh/Bcg locus: Natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med 1995; 182:655-66.
30. +/bivalent cation antiporter. Biochem J 2001; 354:511-9.
31. Searle S, Bright NA, Roach TI, et al. Localisation of Nramp1 in macrophages: Modulation with activation and infection. J Cell Sci 1998; 111:2855-66.
32. Wyllie S, Seu P, Gros JA. The natural resistance-associated macrophage protein 1 Slc11a1 (formerly Nramp1) and iron metabolism in macrophages. Microbes Infect 2002; 4:351-9.
33. Brown DH, Lafuse WP, Zwilling BS. Stabilized expression of mRNA is associated with mycobacterial resistance controlled by Nramp1. Infect Immun 1997; 65:597-603.
34. Hentze MW. Determinants and regulation of cytoplasmic mRNA stability in eukaryotic cells. Biochim Biophys Acta 1991; 1090:281-92.
35. Gly169. Biochem J 2000; 351:687-96.
36. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
37. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20.
38. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in fatal meningococcal disease. Lancet 1997; 349:1912-3.
39. Eskdale J, Gallagher G, Verwij CL, Keijsers V, Westendorp RGJ, Huizinga TWJ. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95:9465-70.
40. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24.
41. Gong JH, Zhang M, Modlin RL, et al. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun 1996;64:913-8.
42. Fulton SA, Cross JV, Toossi ZT, Boom WH. Regulation of interleukin-12 by interleukin-10, transforming growth factor-β, tumor necrosis factor-α, and interferon-γ in human monocytes infected with Mycobacterium tuberculosis H37Ra. J Infect Dis 1998; 178:1105-14.
43. Zhang M, Gong J, Iyer DV, Jones BE, Modlin RL, Barnes PF. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994;94:2435-42.
44. Barnes PF, Chatterjee D, Abrams JS, et al. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan: Relationship to chemical structure. J Immunol 1992; 149:541-7.
45. Zhang M, Gong J, Yang Z, Samten B, Cave D, Barnes PF. Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis 1999; 179:1213-7.
46. Holland SM. Cytokine therapy of mycobacterial infection. Adv Intern Med 2000;45:431-51.